NOVIAN Health Presents at the “Investment in Innovation (IN3) Medical Device
Summit: A Preview of Early-Stage Medical Technology Companies” TM
San Francisco – June 18, 2008 – Henry R. Appelbaum “Chip”, President and Chief
Executive Officer and Director of NOVIAN Health, Inc., presented at the In3 Medical Device
Summit held in San Francisco, CA. The In3 Medical Device Summit previews early-stage
medical technology companies and engages industry dealmakers, including senior executives
from the device industry and healthcare investment community. Mr. Appelbaum highlighted
the company’s accomplishments and the anticipated commercialization of NovilaseTM,
NOVIAN Health’s FDA-cleared treatment for fibroadenomas (benign tumors) of the breast.
NOVIAN Health Inc., located in Chicago, is a privately held company with
proprietary technology for the treatment of tumors using Interstitial Laser Therapy (ILT). The
company has developed, tested, and patented a minimally-invasive procedure that uses ILT
(controlled heating) for the ablation of breast tumors as an alternative to the surgically
invasive, traditional “lumpectomy.” ILT offers significant advantages over surgical removal
including minimal scarring, quicker recovery times, and only requiring local anesthesia.
NOVIAN Health received its first FDA 510k clearance for fibroadenomas of the breast in
2007 and expects to offer its technology at centers around the country. Approval for
malignant tumors will also be sought.
